Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase 1/2 Clinical Study of the Safety and Efficacy of Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

NCT07535710 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT07535710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07535710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase 1/2 Clinical Study of the Safety and Efficacy of Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
March 30, 2026
Completion date
December 31, 2028
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma (ctcl), cutaneous t-cell lymphoma refractory, cutaneous t-cell lymphoma, relapsed, sezary syndrome